buyWeak cluster of 4
Chase C. Leavitt bought $7,250 of ONCT
General Counsel/Secretary at Oncternal Therapeutics, Inc.. 25,000 shares at an average of $0.29, traded Apr 12, 2023, filed Apr 14, 2023.
Conviction score
36Value
$7,250
25,000 shares
Holdings after
106,901
+31% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$7k at market
- +6Relative to holdingsHoldings up 31%
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-024264, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 12, 2023 | POpen-market purchase Common Stock | +15,000 | $0.29 | $4,350 | 96,901 | Apr 14, 2023 |
| Apr 13, 2023 | POpen-market purchase Common Stock | +10,000 | $0.29 | $2,900 | 106,901 | Apr 14, 2023 |
Related signals
Other insiders at Oncternal Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | ONCTbuy Oncternal Therapeutics, Inc. | Robert James Wills director | $28k 3,086 shares | +45% | |
| 30Weak | ONCTbuy Oncternal Therapeutics, Inc. | Robert James Wills director | $59k 6,914 shares | - | |
| 23Weak | ONCTbuy Oncternal Therapeutics, Inc. | David F Hale director | $8,859 980 shares | - | |
| 35Weak | ONCTsell Oncternal Therapeutics, Inc. | Robert James Wills director | $8,859 980 shares | -100% | |
| 21Weak | ONCTbuy Oncternal Therapeutics, Inc. | Gunnar F. Kaufmann Chief Scientific Officer | $9,824 28,000 shares | +42% | |
| 56Moderate | Oncternal Therapeutics, Inc. | James B Breitmeyer Chief Executive Officer | $44k 150,000 shares | +322% | |
| 43Moderate | Oncternal Therapeutics, Inc. | Richard G Vincent Chief Financial Officer | $8,961 30,000 shares | +24% | |
| 33Weak | Oncternal Therapeutics, Inc. | Salim Yazji Chief Medical Officer | $7,200 25,000 shares | +18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.